Inhibition of Sonic Hedgehog and Notch Pathways Enhances Sensitivity of CD133+ Glioma Stem Cells to Temozolomide Therapy

Malignant gliomas are currently treated with temozolomide (TMZ), but often exhibit resistance to this agent. CD133+ cancer stem cells, a population believed to contribute to the tumor’s chemoresistance, bear the activation of Notch and Sonic hedgehog (SHH) pathways. In this study, we examined whether inhibition of both pathways enhances the efficacy of TMZ monotherapy in the context of glioma stem cells. Transcriptional analysis of Notch and SHH pathways in CD133+-enriched glioma cell populations showed the activity of these pathways. CD133+ cells were less susceptible to TMZ treatment than the unsorted glioma counterparts. Interestingly, Notch and SHH pathway transcriptional activity in CD133+ glioma cells was further enhanced by TMZ exposure, which led to NOTCH 1, NCOR2, and GLI1 upregulation (6.64-, 3.73-, and 2.79-fold, respectively) and CFLAR downregulation (4.22-fold). The therapeutic effect of TMZ was enhanced by Notch and SHH pathway pharmacological antagonism with GSI-1 and cyclopamine. More importantly, simultaneous treatment involving TMZ with both of these compounds led to a significant increase in CD133+ glioma cytotoxicity than treatment with any of these agents alone (P < 0.05). In conclusion, CD133+ glioma cells overexpress genes involved in Notch and SHH pathways. These pathways contribute to the chemoresistant phenotype of CD133+ glioma cells, as their antagonism leads to an additive effect when used in combination with TMZ.

[1]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[2]  Guido Nikkhah,et al.  NOTCH Pathway Blockade Depletes CD133‐Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts , 2009, Stem cells.

[3]  C. Kenific,et al.  Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemia , 2009, British journal of pharmacology.

[4]  Stephen Yip,et al.  MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance , 2009, Clinical Cancer Research.

[5]  Mark Bernstein,et al.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. , 2009, Cell stem cell.

[6]  Tatsuya Ozawa,et al.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.

[7]  D. Nam,et al.  Prospective identification of cancer stem cells with the surface antigen CD133. , 2009, Methods in molecular biology.

[8]  P. Babu,et al.  Wnt/β-catenin/Tcf Signaling Pathway Activation in Malignant Progression of Rat Gliomas Induced by Transplacental N-Ethyl-N-Nitrosourea Exposure , 2009, Neurochemical Research.

[9]  Hui Wang,et al.  c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells , 2008, PloS one.

[10]  B. Ang,et al.  Characterization of a side population of astrocytoma cells in response to temozolomide. , 2008, Journal of neurosurgery.

[11]  R. McLendon,et al.  Targeting cancer stem cells through L1CAM suppresses glioma growth. , 2008, Cancer research.

[12]  T. Palaga,et al.  Defects in Notch1 upregulation upon activation of T Cells from patients with systemic lupus erythematosus are related to lupus disease activity , 2008, Lupus.

[13]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Hall,et al.  Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. , 2008, Stem cells and development.

[15]  D. Wion,et al.  Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. , 2007, Cancer letters.

[16]  A. Olivi,et al.  Cyclopamine‐Mediated Hedgehog Pathway Inhibition Depletes Stem‐Like Cancer Cells in Glioblastoma , 2007, Stem cells.

[17]  G. Zheng,et al.  Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells , 2007, Molecular and Cellular Biochemistry.

[18]  M. K. Cooper,et al.  Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells , 2007, Oncogene.

[19]  Mitchel S Berger,et al.  Contribution of Notch signaling activation to human glioblastoma multiforme. , 2007, Journal of neurosurgery.

[20]  C. Brantsing,et al.  Differentiation of human mesenchymal stem cells and articular chondrocytes: Analysis of chondrogenic potential and expression pattern of differentiation‐related transcription factors , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[21]  P. Sánchez,et al.  HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and Tumorigenicity , 2007, Current Biology.

[22]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[23]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[24]  E. Holland,et al.  Notch signaling enhances nestin expression in gliomas. , 2006, Neoplasia.

[25]  M. Caron,et al.  Smoothened Signal Transduction Is Promoted by G Protein-Coupled Receptor Kinase 2 , 2006, Molecular and Cellular Biology.

[26]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[27]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[28]  Q. Su,et al.  Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. , 2005, Cancer research.

[29]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[30]  James D. Griffin,et al.  Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling , 2003, Molecular and Cellular Biology.

[31]  Jussi Taipale,et al.  Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. , 2002, Genes & development.

[32]  Jussi Taipale,et al.  Small molecule modulation of Smoothened activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Jiang Shou,et al.  Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA , 2002, Oncogene.

[34]  P. Johnson,et al.  Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  H. Weiner,et al.  The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. , 2001, Development.

[36]  M. Scott,et al.  Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine , 2000, Nature.

[37]  B. Osborne,et al.  Arbiter of differentiation and death: Notch signaling meets apoptosis , 1999, Journal of cellular physiology.

[38]  B. Howard,et al.  Wnt Signaling Induces GLT‐1 Expression in Rat C6 Glioma Cells , 1999, Journal of neurochemistry.

[39]  S. Artavanis-Tsakonas,et al.  Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .

[40]  M. Christmann,et al.  Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. , 1998, Carcinogenesis.

[41]  G. Aquilina,et al.  Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage , 1993, Nature.

[42]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.